Eli Lilly and Co (HAM:LLY) Total Payout Yield %: 1.01 (As of Jul. 07, 2026)


HAM:LLY Eli Lilly and Co HAM:LLY
96 GF Score
Price €1,053.80
GF Value €1,219.31
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eli Lilly and Co Total Payout Yield %?

Eli Lilly and Co HAM:LLY +0.08% 96 Total Payout Yield % is 1.01 as of Jul. 07, 2026. GuruFocus rates HAM:LLY with a GF Score™ of 96/100 and a GF Value™ of €1,219.31 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Eli Lilly and Co's current Total Payout Yield % is 1.01%.


Eli Lilly and Co Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.


Eli Lilly and Co Total Payout Yield % Related Terms


Eli Lilly and Co Total Payout Yield % Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Total Payout Yield % Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Payout Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.64 1.46 0.94 1.02 0.99

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Payout Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.40 1.19 1.26 1.19 1.91

HAM:LLY vs JNJ, ABBV, MRK: Total Payout Yield % Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co Total Payout Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Total Payout Yield % falls into.


HAM:LLY
96GF Score
Eli Lilly and Co HAM:LLY
Total Payout Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Eli Lilly and Co's Total Payout Yield % for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Market Cap
=- (-3508.232 + 0 + -4597.936) / 818831.48
=0.99%

Eli Lilly and Co's annualized Total Payout Yield % for the quarter that ended in Mar. 2026 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) * Annualized Factor / Market Cap
=- (-2037.94 + 0 + -1339.02) * 4 / 706937.2
=1.91%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Yield % →
What does a Total Payout Yield % of 1.01 mean?
Eli Lilly and Co (HAM:LLY) has a Total Payout Yield % of 1.01 as of Jul. 07, 2026. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on Eli Lilly and Co and its competitors.
Is Eli Lilly and Co's Total Payout Yield % too high?
Eli Lilly and Co's current Total Payout Yield % is 1.01. Overall, Eli Lilly and Co has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Total Payout Yield % compare to JNJ and ABBV?
Eli Lilly and Co's Total Payout Yield % of 1.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Yield % for a Drug Manufacturers company?
A good Total Payout Yield % depends on the Drug Manufacturers industry context. However, Total Payout Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Yield % mean?
A high Total Payout Yield % can signal that a stock is expensive relative to its fundamentals. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on Eli Lilly and Co and its competitors. Eli Lilly and Co's current Total Payout Yield % is 1.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (HAM:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is €1,219.31, compared to a current price of €1,053.80 — trading 13.6% below its estimated fair value. The current Total Payout Yield % is 1.01. Eli Lilly and Co's overall GF Score™ is 96/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Yield % calculated?
Total Payout Yield % is calculated from a company's financial statements. For Eli Lilly and Co (HAM:LLY), the current Total Payout Yield % is 1.01 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (HAM:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of €1,053.80 is trading 13.6% below its estimated GF Value™ of €1,219.31. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for HAM:LLY:

  • Total Payout Yield %: 1.01
  • GF Value™: €1,219.31 vs. price of €1,053.80 (13.6% below fair value)
  • GF Score™: 96/100 with 6 warning signs

No single metric tells the full story. See the HAM:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
96GF Score

Get the complete analysis for HAM:LLY

Total Payout Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1,053.80
Price
€1,219.31
GF Value